Shanghai Zhimeng Biopharma Inc. is a startup biotech founded in 2018 by seasoned pharmaceutical industry veterans. Located in the economy-vibrant and resource-rich Zhangjiang High-Tech Park of Shanghai, China, Zhimeng is developing medicines for the treatment of chronic hepatitis B (CHB) and severe neurological diseases with great unmet medical needs.
Pioneers in Chronic Hepatitis B Drug Development
Realizing the complexity of the pathogenesis of chronic hepatitis HBV infection, Zhimeng has adopted a comprehensive approach to tackle the diseases by directly hitting the hepatitis B virus (HBV) with multiple pronged attacks, as well as restoring the host immune systems. Our goal is to deliver innovative, most effective, safe and affordable therapies to bring a cure for patients suffering from CHB.
Trailblazers in CNS Disorders Drug Development
Zhimeng is also actively developing novel small molecule drugs to treat neurological diseases, such as epilepsy, pains and strokes. Zhimeng’s goal is to provide novel and more effective medicines to improve the quality of life of patients with such diseases.
Every scientific breakthrough reaffirms our covenant with patients. We believe that only through relentless innovation can we fulfill our commitment : 'To bring hope where incurable diseases once prevailed’.